Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All
View Sample

FREE Email Newsletter

DDD Update

Daily news and top headlines for drug research professionals

Overcoming Bias

January 11, 2011 11:05 am | by Matthew Segall, Optibrium Ltd., Cambridge, U.K. and Andrew Chadwick, Tessella plc, Burton upon Trent, U.K. | Articles | Comments

People are notoriously poor at making decisions based on complex uncertain data when there is a lot at stake. When human biases distort drug discovery decision-making, software tools can guide thinking towards objective answers.


A New Global View

January 11, 2011 11:01 am | by Ken Phelps, President and CEO, Camargo Pharmaceutical Services, Cincinnati, Ohio; Vijai Kumar, MD, President and Chief Medical Officer, Excel Life Sciences, Inc., India | Articles | Comments

Given the high cost of moving a promising drug candidate through years of clinical trials, it’s no wonder that more and more drug and device manufacturers have begun conducting at least some of their clinical trials in foreign countries.


Taking Pharma’s Pulse

January 11, 2011 10:48 am | by Rita C. Peters, Editorial Director | Articles | Comments

In order to get a better picture of the drug research market, the editors recently surveyed Drug Discovery & Development readers to measure interests, concerns, and research trends. Some results were quite predictable. Others were a little surprising. Read the opinions, and add your own.


Optimizing the Antibody–Flow Cytometry Combination

January 11, 2011 10:33 am | by Mike May, Contributing Editor | Articles | Comments

Tracking specific components in complex samples plays a fundamental role in many aspects of modern drug discovery and development. To simultaneously measure multiple cell parameters, researchers can combine flow cytometry and multi-color antibody kits.


The Patient in the Petri Dish

January 11, 2011 10:24 am | by Alan Dove, PhD, Contributing Editor | Articles | Comments

It’s the drug developer’s nightmare: the compound that looked great in early screens turns out to be toxic in an expensive animal model—or worse, in clinical trials. Can a new generation of cellular assays come to the rescue?


Particle Characterization Services

January 11, 2011 7:09 am | Product Releases | Comments

Beckman Coulter will now refer customers seeking particle characterization services to ImmunoSite Technologies and ImmunoSite will perform those services using Beckman Coulter particle characterization instrumentation.


Contrast Agent

January 11, 2011 7:02 am | Product Releases | Comments

Targestar P-HF, a perfusion contrast agent specifically designed to be used with high frequency ultrasound scanners, is restricted to the vascular compartment and enables visualization of the vasculature and quantification of blood flow in animal studies.


Liquid Pistons Could Change Drug Delivery

January 11, 2011 6:52 am | News | Comments

A few unassuming drops of liquid locked in a very precise game of "follow the leader" could one day be found in mobile phone cameras, medical imaging equipment, implantable drug delivery devices, and even implantable eye lenses.


Gene Therapy Helps Treat Beta Thalassemia

January 11, 2011 6:47 am | News | Comments

Researchers report a gene therapy strategy that improves the condition of a mouse model of an inherited blood disorder, Beta Thalassemia. The gene correction involves using unfertilized eggs from afflicted mice to produce a batch of embryonic stem cell lines.


Camargo Appoints New CMO

January 11, 2011 6:41 am | News | Comments

Camargo Pharmaceutical Services, a full-service clinical research organization specializing in end-to-end drug development, has announced the company’s appointment of Ray Dawkins, MD, as chief medical officer.


Nikon Signs Agreement with Agilent

January 11, 2011 6:37 am | News | Comments

Nikon Instruments Inc., an innovator of advanced optical instruments, announced an agreement with Agilent Technologies, a technology leader in chemical analysis and life sciences, for distribution in the Americas of Agilent's MLC400 monolithic laser combiner systems.


InSite Files IND for ISV-101

January 11, 2011 6:32 am | News | Comments

InSite Vision Incorporated announced that it has filed an Investigational New Drug application for ISV-101 with the U.S. Food and Drug Administration. ISV-101 is InSite Vision's novel compound being developed to treat dry eye disease.



January 11, 2011 6:28 am | News | Comments

Merck announced that the new drug application for the company's investigational extended-release formulation of JANUMET for type 2 diabetes has been accepted for standard review by the U.S. Food and Drug Administration.


J & J Rumored to Be Interested in Smith & Nephew

January 11, 2011 6:23 am | News | Comments

British orthopedic maker Smith & Nephew has reportedly rejected an acquisition offer from U.S. health care giant Johnson & Johnson. Britain's Sky News reported that Smith & Nephew had rejected an offer valued at 7 billion pounds, or nearly $10.9 billion.


BMS And Pharmasset Running Joint Trial

January 11, 2011 6:19 am | News | Comments

Bristol-Myers Squibb Co. and Pharmasset Inc. said they will run a clinical trial testing the combination of two hepatitis C drugs, one developed by each company. Pharmasset is developing PSI-7977, while Bristol-Myers Squibb's drug is designated BMS-790052.



You may login with either your assigned username or your e-mail address.
The password field is case sensitive.